Respiratory Medicine
Volume 102, Issue 12 , Pages 1675-1680, December 2008

Pulmonary rehabilitation in idiopathic pulmonary fibrosis: A call for continued investigation

  • Jeffrey J. Swigris

      Affiliations

    • Autoimmune Lung Center, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 303 398 1621; fax: +1 303 398 1040.
  • ,
  • Kevin K. Brown

      Affiliations

    • Autoimmune Lung Center, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
  • ,
  • Barry J. Make

      Affiliations

    • COPD Program, National Jewish Medical and Research Center, Denver, CO, USA
  • ,
  • Frederick S. Wamboldt

      Affiliations

    • Division of Psychosocial Medicine, National Jewish Medical and Research Center, Denver, CO, USA

Received 28 May 2008; accepted 24 August 2008. published online 13 October 2008.

Summary 

Idiopathic pulmonary fibrosis (IPF) is a devastating disease that afflicts patients with relentlessly progressive shortness of breath [Joint Statement of the American Thoracic Society and the European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med 2000;161:646–641]. Despite nearly 30 years of intense investigation, effective therapy for IPF remains elusive; median survival rates have stubbornly remained less than five years from the time of diagnosis [Bjoraker JA, Ryu JH, Edwin MK, Meyers J, Tazelaar H, Schroeder D, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199–2032, Flaherty KR, Thwaite E, Kazerooni EA, Gross B, Toews GB, Colby TV, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58:143–483], and no medical therapy has been proved to be in any way effective for the treatment of this disease. Without medications that help IPF patients live longer, an important question to ask is whether there are interventions that might allow these people to live better—to be more active; to experience less dyspnea, less depression, less anxiety; to possess a greater sense of control over their disease; and to have better quality of life. Pulmonary rehabilitation helps to accomplish many of these goals in patients with chronic obstructive pulmonary disease, and emerging data suggest that it may do the same for patients with IPF.

Keywords: Pulmonary fibrosis, Pulmonary rehabilitation, Dyspnea

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The work in this manuscript is the original work of the stated authors.

PII: S0954-6111(08)00312-0

doi:10.1016/j.rmed.2008.08.014

Respiratory Medicine
Volume 102, Issue 12 , Pages 1675-1680, December 2008